drugset / Trial / NCT00697853
Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine (2 Doses), and of Engerix™-B (3 Doses) in Healthy Adults
RandomizedParallel-groupOpen-labelPrevention
Summary
This study is undertaken to assess the immune response and safety profile of 4 lots of the novel adjuvanted hepatitis B vaccine that were formulated following different processes, with Engerix™-B as the control vaccine
Timeline
- Start
- 1998-11
- Primary completion
- 1999-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Engerix-B | Vaccine | — | Intramuscular |
| Subject | HBV-MPL vaccine 208129 | Vaccine | — | Intramuscular |